HTML Microdata document

This HTML5 document contains 38 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

Prefix	IRI
n2	http://linked.opendata.cz/resource/drugbank/drug/
dcterms	http://purl.org/dc/terms/
n6	http://linked.opendata.cz/resource/drugbank/drug/DB05494/identifier/chemspider/
n12	http://bio2rdf.org/drugbank:
n9	http://linked.opendata.cz/resource/drugbank/drug/DB05494/identifier/bindingdb/
adms	http://www.w3.org/ns/adms#
n10	http://linked.opendata.cz/resource/drugbank/drug/DB05494/identifier/pubchem-compound/
rdf	http://www.w3.org/1999/02/22-rdf-syntax-ns#
n7	http://linked.opendata.cz/resource/drugbank/drug/DB05494/identifier/drugbank/
owl	http://www.w3.org/2002/07/owl#
n3	http://linked.opendata.cz/ontology/drugbank/
n4	http://linked.opendata.cz/resource/drugbank/property/
xsdh	http://www.w3.org/2001/XMLSchema#

Statements

Subject Item: n2:DB05494
rdf:type: n3:Drug
n3:description: CP-4055 is a fatty acid derivative of cytarabine, an approved cytotoxic cancer drug. Cytarabine has limitations such as minimal uptake in solid tumours and is only used to treat leukaemia. CP-4055 is designed to overcome this limitation and has shown considerable uptake in solid tumour cells. CP-4055 is a patented new chemical entity of the nucleoside analog class, with improved biological properties and the potential to treat solid tumours such as non-small cell lung cancer, malignant melanoma and ovarian cancer.
n3:generalReferences: # Bergman AM, Kuiper CM, Voorn DA, Comijn EM, Myhren F, Sandvold ML, Hendriks HR, Peters GJ: Antiproliferative activity and mechanism of action of fatty acid derivatives of arabinofuranosylcytosine in leukemia and solid tumor cell lines. Biochem Pharmacol. 2004 Feb 1;67(3):503-11. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15037202
n3:group: investigational
n3:indication: Investigated for use/treatment in leukemia (unspecified) and melanoma.
owl:sameAs: n12:DB05494
dcterms:title: CP-4055
adms:identifier: n6:576 n7:DB05494 n9:50004746 n10:596
n3:mechanismOfAction: CP-4055 is the lipophilic 5'-elaidic acid ester of the deoxycytidine analog cytosine arabinoside (cytarabine; Ara-C) with potential antineoplastic activity. As a prodrug, CP-4055 is converted intracellularly into cytarabine triphosphate by deoxycytidine kinase and subsequently competes with cytidine for incorporation into DNA, thereby inhibiting DNA synthesis. Compared to cytarabine, CP-4055 shows increased cellular uptake and retention, resulting in increased activation by deoxycytidine kinase to cytarabine triphosphate, decreased deamination and deactivation by deoxycytidine deaminase, and increased inhibition of DNA synthesis. This agent also inhibits RNA synthesis, an effect not seen with cytarabine.
n3:IUPAC-Name: n4:271B455E-363D-11E5-9242-09173F13E4C5
n3:InChI: n4:271B4564-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula: n4:271B4563-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight: n4:271B4560-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight: n4:271B4561-363D-11E5-9242-09173F13E4C5
n3:SMILES: n4:271B4562-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility: n4:271B455C-363D-11E5-9242-09173F13E4C5
n3:logP: n4:271B455D-363D-11E5-9242-09173F13E4C5 n4:271B455A-363D-11E5-9242-09173F13E4C5
n3:logS: n4:271B455B-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count: n4:271B456A-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count: n4:271B456B-363D-11E5-9242-09173F13E4C5
n3:InChIKey: n4:271B4565-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-: n4:271B4566-363D-11E5-9242-09173F13E4C5
n3:Polarizability: n4:271B4568-363D-11E5-9242-09173F13E4C5
n3:Refractivity: n4:271B4567-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count: n4:271B4569-363D-11E5-9242-09173F13E4C5
n3:Bioavailability: n4:271B4570-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter: n4:271B4572-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule: n4:271B4573-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings: n4:271B456F-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge: n4:271B456E-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five: n4:271B4571-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name: n4:271B455F-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-: n4:271B456C-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-: n4:271B456D-363D-11E5-9242-09173F13E4C5